argenx SE
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARGX.BR research report →
About the company
argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions. Its operational reach extends across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's primary drug candidate, efgartigimod, is currently in advanced stages of clinical investigation.
- CEO
- Timothy Van Hauwermeiren
- IPO
- 2014
- Employees
- 1,599
- HQ
- Breda, NL
Price Chart
- Market Cap
- $46.42B
- P/E
- 47.73
- P/S
- 15.61
- P/B
- 7.14
- EV/EBITDA
- 46.47
- Div Yield
- 0.00%
- Gross Margin
- 89.00%
- Op Margin
- 25.64%
- Net Margin
- 33.42%
- ROE
- 16.82%
- ROIC
- 11.74%
- Revenue
- $4.15B · 84.75%
- Net Income
- $1.34B · 61.42%
- EPS
- $21.94 · 57.61%
- Op Income
- $1.03B
- FCF YoY
- 1136.11%
- 52W High
- $813.60
- 52W Low
- $456.60
- 50D MA
- $713.64
- 200D MA
- $699.85
- Beta
- -0.03
- Avg Volume
- 96.73K
Get TickerSpark's AI analysis on ARGX.BR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ARGX.BR coverage
Recent articles, reports, and earnings notes.
No research on ARGX.BR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARGX.BR report →Similar companies
Peers in the same neighborhood.